ADDF Drug Development RFP
Supports Alzheimer’s and dementia drug development from preclinical readiness to early clinical testing across diverse modalities.
Eligibility · Global — open worldwide
The Alzheimer's Drug Discovery Foundation (ADDF), a New York-based 501(c)(3) venture-philanthropy organization founded in 1998 by Leonard and Ronald Lauder, operates the Drug Development RFP to accelerate IND-enabling studies and early-phase clinical trials for Alzheimer's disease and related dementias. Since its founding, ADDF has distributed nearly $400 million across 792 programs in 21 countrie…
IND-enabling studies and early-phase clinical trials for Alzheimer's disease and related dementias. Eligible modalities: small molecules, peptides, antibodies, gene therapies, ASOs, stem cells, devices. Anti-amyloid and cholinesterase inhibitor proposals excluded.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline